東栄新薬 Company Profile

Tōei Shinyaku has obtained a patent for the measurement method of the main component β-glucan in Agaricus ~ Useful for diagnosing fungal diseases and measuring β-glucan content in supplements ~ Tōei Shinyaku Co., Ltd. (located in Mitaka City, Tokyo, CEO: Akira Motoi) has established a measurement method for β-glucan, the main component of Agaricus, as a result of research conducted in collaboration with the Department of Immunology at Tokyo University of Pharmacy and Life Sciences, focusing on our field-cultivated Agaricus KA21 strain (hereinafter referred to as Agaricus KA21). We are pleased to announce that this research outcome has been registered as a patent under the title "Measurement Method for β-1,6-Glucanase Mutant and β-1,6-Glucan."

Toei Shinyaku Co., Ltd. conducted a satisfaction survey among veterinarians regarding the outdoor-cultivated Agaricus (KA21 strain). [About the Survey] Test Product: A 300mg granule supplement made from outdoor-cultivated Agaricus (KA21 strain) from Brazil, without any additives. Survey Details: The product was orally administered at a rate of one granule per day for one month to 94 dogs and cats weighing 5-6 kg, and the satisfaction of veterinarians was investigated. Target Veterinarians: 44 facilities with 44 participants Survey Method: Internet survey conducted by Betpia from June to July 2021 [Results] The administration of outdoor-cultivated Agaricus (KA21 strain) confirmed a very high satisfaction rate among veterinarians, ranging from 80.6% to 93.1%.* *The satisfaction levels were categorized as very satisfied, satisfied, or dissatisfied, with values above "satisfied" being reported. **Part of the results from this survey was presented at the 25th Annual Conference of the Japanese Society of Veterinary Dermatology (March 27, 2022, Venue: International Fashion Center Building) in collaboration with the Faculty of Veterinary Medicine at Azabu University and the Department of Immunology at Tokyo University of Pharmacy and Life Sciences.